Literature DB >> 15032702

Antisense oligonucleotide drug design.

N Schiavone1, M Donnini, A Nicolin, S Capaccioli.   

Abstract

Maneuvering single gene expression is not only an optimal way to study gene function but also an ambitious goal, which will lead to the treatment of a variety of human diseases whose main pathogenetic event is a genetic alteration. The recent efforts focusing on the genome project have led to array based, high throughput, gene expression analysis techniques that allow the study of complex molecular networks. Combining these powerful new technologies with modulation of gene expressions is making it possible to unravel complex molecular networks or, vice versa, to find new gene products responsible for pathological conditions on which exogenous modulation can be productive. Efficient and specific modulation of gene expression can be obtained either by producing transgenic or gene knockout organisms or cells (gene targeting), or by treating organisms or cells with short synthetic nucleic acid segments in antisense orientation with respect to the targeted mRNAs (mRNA targeting by antisense strategy). While genome manipulation is a time consuming and expensive approach, requiring invasive intervention, the "antisense strategy" is characterized by high flexibility resulting from safeness, specificity, reversibility, modulability, and low cost. The rationale of the antisense strategy is that, once one gene sequence is known, its expression can be silenced by application of synthetic single-strand nucleic acid segments (oligonucleotides) whose sequence is in antisense orientation compared to the targeted mRNA. Recently, this "informational" strategy has been boosted by the discovery of the RNA interference: a natural mechanism by which cells are thought to fight detrimental exogenous viruses and endogenous transposons. Despite promising futures, antisense-based therapeutics are far from being an established reality. This review analyses the recent improvements in antisense-based gene expression modulation, focuses on the treatment of diseases in the light of the past, and provides our personal findings on this topic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15032702     DOI: 10.2174/1381612043452956

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Comparison of microplate and macrodilution methods in time-kill study of new antimicrobial drugs.

Authors:  Ying Zhou; Zheng Hou; Chao Fang; Xiaoyan Xue; Fei Da; Yukun Wang; Hui Bai; Xiaoxing Luo
Journal:  Folia Microbiol (Praha)       Date:  2012-06-09       Impact factor: 2.099

2.  Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro.

Authors:  Shan-zhi Gu; Xin-han Zhao; Ling-xiao Zhang; Li Li; Zhi-yu Wang; Min Meng; Gai-li An
Journal:  J Zhejiang Univ Sci B       Date:  2009-03       Impact factor: 3.066

3.  Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.

Authors:  David A Stein; Claire Y-H Huang; Shawn Silengo; Adams Amantana; Stacy Crumley; Robert E Blouch; Patrick L Iversen; Richard M Kinney
Journal:  J Antimicrob Chemother       Date:  2008-06-19       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.